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ABSTRACT
Hot melt extrusion (HME) is an old technology that has been recently adapted to be used
in the pharmaceutical industry. HME is a continuous process that is widely used to produce a solid
dispersion matrix. The aim of this dissertation is to evaluate different factors that will affect the
pharmaceutical formulation properties that are produced using HME. For HME, there are different
variables that will affect the product quality such as processing parameters, material selection,
material ratio, and the presence of gas or moisture. One aim of this study is to find the most
significant factor that affects the product properties using the simplest design of experiment.
Material selection and the ratio between the materials will be extensively evaluated using
carbamazepine as a model drug. Moisture content and gas introduced during the process will be
assessed and illustrate the best method to remove them. Process parameters show a significant
effect on the product quality. Polymer selection and the ratio between the polymers show a great
impact on drug dissolution and stability studies. Effective degassing has successfully enhanced the
overly product quality features such as dissolution, shape, drug content and stability.
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CHAPTER 1
HOT MELT EXTRUSION IN THE PHARMACEUTICAL INDUSTRY

1

INTRODUCTION
Hot Melt Extrusion (HME) is one of the oldest production technique that human was
developed. HME has been used for metal production since 1797 (1). Over the years, the HME
technique was used in different industries such as plastic, food and recently in the pharmaceutical
industry. Extrusion is a Greek word meaning push out; in the simplest terms, HME is essentially
processing materials under high shear energy using elevated temperatures and pressures (2).
Several articles have demonstrated and explored HME as a promising technique for
pharmaceutical production (3). HME begin to use in the pharmaceutical industry as an innovative
and promising process for manufacturing a number of pharmaceutical products. HME has shown
its benefits as a continuous process, solvent free, with fewer processing steps, compared to other
pharmaceutical techniques. Another advantage of HME is the ability of producing a wide range of
dosage forms in various shapes and sizes, for example, tablets (4), granules (5), pellets (6), films
(7), and implant devices (8). Additionally, several pharmaceutical products with different
properties were successfully produced by HME, such as control release (4), taste masking (9), and
fast dissolving tablets (10). All these application depends on mixing the active pharmaceutical
ingredient (API) with a biodegradable non-active carrier.
In general, there are many types of extruders that are used to produce different products
with different shapes and sizes. All of the existing extruders are either a ram extruder or a screw
extruder. A ram extruder pressurizes the material in a heated barrel where it stays until the material
melts. Then, it forces the material into a die to give the desirable shape (3). The advantage of this
kind of extruder is the simplicity of the design. However, the main drawback in this kind of
2

extruder is the lack of mixing homogeneity of materials (3). For that reason, this extruder is rarely
used for pharmaceutical production. The second type of extruder is the screw extruder. A screw
extrusion consists of a rotating screw(s) inside a heated barrel. Screw extruders have an advantage
over the ram extruders since the screws adequately mix the materials during melting. A screw
extruder provides more homogeneous-mixing and higher shearing force compared with a ram
extruder. For the pharmaceutical application, homogeneity of mixing is the key feature of the
product quality to produce a uniform pharmaceutical product. Therefore, the screw extruder is the
most common one to be used in the pharmaceutical application. Typically, any screw extruder will
consist of the same essential following components:
1. Feeders.
2. Barrels.
3. Driving unit (motor).
4. Screws.
5. Down- stream processing equipment.
1. Feeder:
In HME, feeding the raw materials into the extruder is the first processing step. For largescale production, usually there are several feeding zones to insure a proper feeding. There are two
types of feeders: volumetric feeder and gravimetric feeder. The use of a feeder depends mainly on
the material properties and the number of screws. The angle of the hopper used normally should
always be greater than the angle of repose of the materials extruded. This is to maintain a good
flow property during the feeding process (11). In addition, a force-feeding device is sometimes
used if a cohesive material or a fine powder will be used.
3

2. Barrel:
An extruder barrel keeps the materials inside and contains the heating/cooling element. The
heating elements are usually electric heater bands, while cooling is provided using an air or water
circulator over the barrel. Additionally, the barrel may have some holes for pressure prop, fluid
injector, temperature sensors and gas vacuum. Usually, all extruders have the same barrel design.
For this reason, a formulator cannot change anything regarding the barrel. Barrel length/diameter
ratios also determine residence time and processing capacity (12). A high friction coefficient in
the barrel and a low friction coefficient of the screw surface will enhance the materials' movement
at that section.
3. Driving unit (motor)
This is to provide the energy required to drives the screw(s). This part will control the
screw speed and shearing energy force. The electric motor is most commonly used in the
pharmaceutical industry. Processing parameters such as screw speed, temperature and feeding rate
will affect the energy requirement for the motor. It has been reported that there is a relationship
between back-pressure and energy consumption during extrusion. Increasing the screw speed or
feeding rate will increase the back-pressure on the extruder head, and as a result the total energy
will be increase (13).
4. Screws
Extruders are classified into two types based on the number of screws:

Single Screw Extruder:
Single screw extruder is mechanically a very simple extruder. It contains one single screw
in the extrusion barrel. The advantage of this design is that the feed system can be independent of
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screw speed. Different screws can be used to enhance the mixing for example pin, diamond, and
pineapple mixer (14). In the pharmaceutical industry, such extrusion is very unlikely to be used
due to the poor intense mixing.
Twin Screw Extruder:
In this extruder, two screws are designed side by side. Twin-screw extruders have several
advantages over single screw extruders, such as smooth material feeding, and high mixing
capacity. These advantages will provide better homogeneity of mixing and more heat distribution.
In addition, two screw designs will give a chance for different configurations and different
processing conditions in different zones. Two different screw rotations can be used; the screws can
rotate either in the same or opposite direction.
A. Counter rotating (opposite direction) screw extruder:
The counter-rotating design is usually used when high shear force is required. Such rotation
is good for dispersing extruded particles in the molten mixture. Unfortunately, counter-rotating
extruders have some disadvantages, such as high pressure, air entrapment, and low maximum
screw speeds. Therefore, counter rotation is not generally used in the pharmaceutical industry.
B. Co- rotating (same direction) screw extruder:
This is the most common screw rotation used in the pharmaceutical application. It has
several advantages compared with counter rotating. Some of these advantages include high-speed
screw, high output, good mixing, and the most important advantage is the screw configuration
options. Using a co-rotating twin-screw will gave the option to use elements with different
geometrics. This flexibility allows the formulation scientist to choose the optimal screw
configuration to meet the application requirements. Screw configuration has recently expanded the
extrusion limits, such as extruder torque, shearing force, and using heat labile materials (15, 16).
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Co-rotating screws can be intermeshing or non-intermeshing. A non-intermeshing screw is able to
process highly viscous materials, but it generates high heat energy. On the other hand,
intermeshing screws are self-cleaning and can distribute the heat very well (3). For that, co-rotating
intermeshing screws are extensively used in the pharmaceutical industry.
The twin-screw extruder has an identical screw design that will have the same pitch, length,
diameter, and helix. Extruder screw has different elements each element has a specific designs for
certain functionality. Understanding each element will help the formulator to solve or overcome
some problems. Each screw may contain one of these three main elements: conveying, melting,
and metering.
1. Conveying element:
This element is to transfer the materials through the extruder with less shearing energy.
Those elements are used to transfer the material from the hopper to the melting section or pushing
the material into the die. This part is designed with large pitch and a single lead geometry. These
features make the conveying elements generate a consistent pressure with high free volume. Due
to the high free volume, these elements are used in feeding, conveying and venting sections (17).
2. Mixing Elements:
Mixing is an essential section in the pharmaceutical HME. Mixing elements provide a high
shearing force to mix the material in the melting section. Those elements can provide two types of
mixing: distributive mixing and dispersive mixing. Distributive mixing is responsible for
homogeneous mixing of the ingredients, while dispersive mixing is for particle size reduction and
distribution (11). Mixing sections consist of a number of single mixing elements. They are
arranged in a way based on offset angle. By increasing the offset angle, the mixing properties
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increase while the conveying properties decrease. This part is for mixing, plasticizing and
dispersing the materials inside the extruder.
Each elementary section may affect the properties of the final extrudates. Depending on
the depth and/or pitch of the element, we can expect different free screw volume and shear stress.
Based on that, the design of the screw has a substantial impact on the process and can be modified
to meet specific requirements such as high or low shear. In the feeding section, for example, large
screw flight depth and pitch are used to decrease the pressure, providing a constant feeding and
gentle mixing. The screw configuration has been reported as a factor affecting the particle size and
shape of the products (16). Also, in another study, it was found that screw configuration may
change the morphology status and the dissolution behavior of the API (18). Screw configuration
models like kneading blocks, reverse conveying and forward-conveying elements may enhance or
control the level of mixing.
5. Down- stream processing equipment.
The last step in the extrusion process is to pump the materials and shape as required.
Downstream processing equipments are used for cooling, cutting or collecting. Down- stream
processing equipment depends primarily on the die geometry. For example, flat dies are design to
produce films and patches. In addition to the die, there is some equipment used to get the final
product shape, such as the face-cut pelletizer, and injection molding. Each one of these pieces of
equipments can be connected to the extruder to perform its work in a continuous process.
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PHARMACEUTICAL FORMULATION MATERIALS
Materials extruded usually consist of API, carrier, and other processing aid materials. The
most important factor for any extruded materials to be suitable for hot melt extrusion is the thermal
stability. During the HME process, the materials will be exposed to different sources of energy
such as temperature, pressure, and shear stress. The physical-chemical transformation might be
induced because of this energy exposure. Therefore, thermal, physical and chemical
characterization of any extruded materials should be carried out before processing.
Carriers: A number of carriers with various glass transition, viscosity, molecular
weight and melting temperatures are available for hot melt extrusion. Carriers may be crystalline,
semi crystalline or amorphous. Pharmaceutical HME requires a suitable carrier material, which is
typically a biodegradable thermoplastic polymer or a combination thereof. In the market, there are
many types of thermoplastic polymers that can be used as carriers, for example:
polyvinylpyrrolidone, hydroxypropylcellulose, and polyvinyllactam. Each polymer has its specific
feature(s) that helps to choose between them.
Plasticizers: Several compounds, either gas, liquid or solid, may be used as softening agents
to facilitate the extrudability of the materials. These materials usually decrease the glass transition
temperatures and the melt viscosity of the polymers. Plasticizers can do that by implanting in the
spaces between polymer chains and forming secondary valence forces (19). Plasticizers such as
stearic acid, castor oil, and glyceryl behenate can be chosen depending on the desired formulation
and compatibility (20). Typically, the processing temperatures are set above the melting point of
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active ingredients and the glass transition temperature of carriers. This method may interfere with
the thermal stability of one of the components. Therefore, plasticizers are used with high melting
point API to enhance its extrudability. Recently, carbon dioxide began to be used as HME
plasticizers (21). Other Processing Aids: Anti-oxidants and thermal stabilizers are used to improve
drug stability and melt fluidity.

9

PROCESSING PARAMETERS
HME is a continuous process; as a result, process monitoring is very critical to achieve a
good quality product. Online monitoring devices include temperature gauges, screw-speed
controller, torque monitor, and pressure gauges. These tools will help to adjust the processing
parameters as required. Processing parameters are the variables that can be changed to optimize
the formulation. Those variables (Table 1-1) depend on the formulation properties, requirement,
and economic factors. Each one has its own function and may affect other variables.
Table 1-1 Extrusion input variables
Adjustable

Configuration

Material

Feed rate

Screw design

Melting point

Screw speed

Barrel design

Molecular weight

Barrel temperature

Die geometry

Density

Feeder

Glass transition temperature

10

AIMS AND OBJECTIVES
All the projects in this dissertation depend on evaluating the HME technique as a method
of producing a solid dispersion system. Solid dispersion is a method that had been used to enhance
the solubility of highly crystalline, poorly water soluble active compounds. Over the past few
decades, drug discovery and development pharmaceutical scientists have produced improved
techniques to generate more selective and powerful new chemical entities. Unfortunately, the
current literature estimates that up to 70% of the new chemical entities are poorly water soluble
(20). A successful pharmaceutical formulation will need to have a sufficient aqueous solubility of
the API in order to achieve sufficient bioavailability (21). This limitation can potentially slow
down the delivery of needed drugs to the market. To address this issue, new processing
technologies have been introduced into the pharmaceutical industry to help solve the increasingly
ubiquitous solubility issue (20). One such approach is the formation of solid dispersions, which
has recently become a widely investigated technique to enhance aqueous solubility.
Over the years, solid dispersion has shown its ability to improve the bioavailability of
active pharmaceutical ingredients. There are several production methods to produce solid
dispersion such as solvent evaporation method, melt evaporation method, lyophilisation technique,
and the more recently developed hot melt extrusion method (21). HME has shown promising
results as an effective approach to produce a solid dispersion matrix. The solid dispersion system
will enhance the dissolution rate, which is the main reason for low water solubility. Solid
dispersion has different mechanisms, such as producing a solid solution, glass solution, amorphous
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formation, and simple eutectic mixtures, to enhance the water solubility and sequentially
bioavailability (22). In most cases, solid dispersion works by more than one mechanism, but
amorphous formation is the main dissolution rate enhancement mechanism. The amorphous state
is thermodynamically more active than the crystalline state (23). This activity makes the
amorphous state highly soluble in water, as no energy is required to break the crystal lattice found
in the crystalline state. However, this high thermodynamic activity make the amorphous state
spontaneously revert to the crystalline state (24). In addition, solid dispersion has some limitations,
including expensive methods of preparation, scale-up of manufacturing restraint, reproducibility
of physicochemical properties (22). Therefore, HME could be the most attractive method of
producing solid dispersion system. HME in addition to the advantages indicated above, is cost
effective and easy technique to scale up (20). The projects presented in this dissertation will
investigate several HME process factors in order to minimize the HME production cost and
enhance the product quality. As shown above, many factors may affect the final properties of a
pharmaceutical formulation. Over the last ten years, the United States food and drug administration
(FDA) started demanding to include quality-by-design (QbD) approach to any new product. QbD
is a method to control the production process to ensure the quality of the final product. HME is
originally adapted from other industries because of that HME is still not well defined for
pharmaceutical application. Recently, QbD for HME processing parameters began evaluated to
optimize the product quality. A full understanding of the factors affecting HME will be the best
method to achieve a good quality by design principles.
The main goal of this dissertation is to demonstrate the effect of HME processing factors
and how to optimize each one to get the best product quality. In order to achieve this goal, the
dissertation will be divided into three different projects. Each project will show the impact of one

12

or more of the factors affecting the HME product. Here are the three main aims that each project
will cover:


Processing parameters.



Material selection and the ratio between the materials.



HME venting influence and importance.
In Chapter 2, processing parameters will be investigated and used to enhance the product

quality. As a continuous process, HME processing parameters have a different influence on the
final product properties. Several studies in the last five years have demonstrated HME processing
parameters' influence on the final product properties (23, 24). In the last few years, large numbers
of research papers have investigated the understanding of the process using different methods such
as studying the variable parameters and in/on line process monitoring. Consequently, the FDA
added the process analytical technology concept to their guidelines. According to the FDA, process
analytical technology (PAT) is sets of techniques aimed to assess the critical process parameters
to ensure the final product quality. Therefore, several research efforts were made regarding the use
of process understanding as a method of product quality control. A simple and effective design is
highly recommended to facilitate the use of PAT and QbD concepts.
Selecting the right polymers and the best ratio between them will be demonstrated in detail
in Chapter 3. HME primarily depends on dispersion of the API into a melted carrier. In most cases,
this carrier is a biodegradable polymer that exhibits its pharmaceutical benefits by enhancing the
drug dissolution rate and inhibiting the recrystallization process (25). For HME, using a suitable
carrier is the most significant factor in producing a superior solid dispersion (24). The polymer
used for HME application depends on its properties, such as thermostability, hydrophylicity, glass
transition temperature, and molecular weight.
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In Chapter 4, moisture and gas removal during the process will be evaluated. Gas removal
will be studied to show its different influence either on extrusion process parameters or on final
product characteristic. In HME, both formulation and process parameters impact the final product
quality as well as one another. For example, API or the carrier moisture content may affect the
extrusion performance. Therefore, it is not possible to focus on formulation requirement without
considering process considerations and vice versa. For that, any slight changes either on
formulation composition or processing parameters will significantly alter the final product's
physicochemical properties.

14
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CHAPTER 2
HOT MELT EXTRUSION PROCESSING PARAMETERS OPTIMIZATION
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ABSTRACT
The objective of this study was to demonstrate the influence of processing parameters of
the Hot Melt Extrusion (HME) on the pharmaceutical formulation properties. Carbamazepine
(CBZ) was selected as a model water insoluble drug. It was incorporated into Soluplus ®, which
was used as the polymeric carrier to produce a solid dispersion model system. The following HME
independent parameters were investigated at different levels: extrusion temperature, screw speed
and screw configuration. Design of experiment (DOE) concept was applied to find the most
significant factor with minimum numbers of experiment runs. A full two level factorial design was
used to evaluate main effects, parameters interactions and total error. The extrudates' CBZ content
and the in-vitro dissolution rate were selected as response variables. Material properties, including
melting point, glass transition, thermal stability and polymorphs changes were used to set the
processing range. In addition to that, extruder torque and pressure were used to find the simplest
DOE model. All of the extruded formulations have demonstrated a higher dissolution rate
compared to the pure drug. Each change of the parameter showed a unique pattern of dissolution
profile, indicating that processing parameters have an influence on formulation properties. 2-level
factorial design was able to evaluate each parameter affect and find the ideal formulation. Screw
configuration and extrusion temperature were the most affecting parameters in this study.

Keywords: hot melt extrusion, design of experiment, process parameters,
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INTRODUCTION
Over the years, hot melt extrusion (HME) has shown promising effectiveness in
pharmaceutical production (1). HME is the process of pumping raw materials with a rotating screw
under elevated temperature and pressure (2). The molten materials are then put through a die to
produce products of uniform shape and size. The extrudates obtained may be in the form of films
or rods that can be processed into the final desirable dosage form (3). Several pharmaceutical
products with different properties, such as immediate release, taste masking, and sustained release
formulations, have been successfully produced by HME.
In HME, there are different processing variables that can be adjusted, including extrusion
temperature, screw speed, feeding rate, and screw configuration (1). Each one has its own function
at the same time each one correlates with the other parameters to control the whole process. For
pharmaceutical extruders, processing parameters are the variables that can be changed to optimize
the formulation. Setting the optimum screw speed or extrusion temperature is the first challenge
in HME. The adjustment of these variables depends on the formulation properties, requirement,
and economic factors. The best method suggested in literature is to use a process parameter chart
to show the correlation between the parameters (4). Since each formulation has its own properties,
each variable may show different influences with each formulation. Therefore, finding the right
and the best processing parameter is a crucial step in HME.
Several articles have been published before showing the influence of processing parameter
on the product quality. In literature, there are several articles demonstrating different methods of
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how to find or optimize the processing parameters. Most of these articles suggest using a design
of experiment (DOE) methods, such as Taguchi (5), Box–Behnken design (6), or Response surface
methodology (6). However, these designs required large numbers of experiment runs to get all the
information required to optimize the formulation. DOE is a statistical method that depends on
studying different factors at different levels by comparing their response or effect. This concept
can be applied to HME application. HME has some variables that can be changed for example
materials, temperature, screw speed, feeding rate, and screw configuration. Each one of those
variables have different influences that can change the drug release or drug content, which can be
used as a response measure for the DOE model.
The main objective of this research is to find the simplest possible statistical method to
optimize the processing parameters. A simple design will show which factor will significantly
affect the formulation and will provide all the information required without the need to run a large
number of experiments. A simple design will save money, time, materials, and will not require a
large amount of API. The current study is to investigate the influence of processing parameters on
the properties of Carbamazepine (CBZ) - Soluplus® melt extrudates. It uses DOE to determine the
effects of changes in the levels for each parameter on the response or behavior of the final product
(7). Design of experiment (DOE) software was used to generate a design space in order to find the
most significant factor that will affect the formulation. The design generated will include all
possible combinations of each level of each of the parameters. This software allows the parameters
to be set either as numeric or categorical factors. This study uses the “full factorial design” from
the DOE. The simplest factorial design has two levels for each parameter. In this study, we
investigated three different parameters at two levels each. Further, we developed an optimized
formulation of CBZ with enhanced solubility utilizing the factorial design data. This work was
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established to find the relationship between HME final product quality and process parameters
using design of experiment (DOE) method. The quality features of the HME products were
analyzed as the response, such as drug release profiles, and drug content. Quality response tests
were performed to evaluate the parameter changes of screw configuration, screw speed and
temperature at different levels.
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MATERIALS AND METHODS
MATERIALS
Carbamazepine was purchased from Afine Chemicals Limited Zhejiang China, and was of
high purity. BASF Chemical Co. (Ludwigshafen, Germany) kindly gifted Soluplus ® (polyvinyl
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer). All other chemicals used
were of analytical grade and obtained from Fisher Scientific (Fair Lawn, NJ, USA). High
performance liquid chromatography (HPLC) grade water was freshly prepared in the laboratory
by Nanopure systems (Barnstead, Dubuque, IA, USA).
MEHODS
Thermo gravimetric analysis
Thermal stability for CBZ and Soluplus were determined by the thermo
gravimetric analysis performed using A Perkin Elmer Pyris 1 thermo gravimetric analyzer (TGA)
equipped with Pyris manager software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport
Ave., Connecticut, USA). Each sample weighed three to eight milligrams and was heated from 20
to 250°C at a heating rate of 10°C/min.

Preparation of solid dispersion
The polymer was sieved using USP mesh screen (#35). The polymer was then blended
with CBZ using a twin shell V-blender (GlobePharma, Maxiblend®) at 25 RPM for 10 min. In this
study, we used a co-rotating twin-screw extruder (11 mm Prism EuroLab, ThermoFisher
Scientific) under different processing conditions. Two different screw configurations were
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selected, one with two mixing zones and another with three mixing zones. After extrusion, the
melted extrudates were cooled to ambient temperature, milled using a comminuting mill
(Fitzpatrick, Model L1A), sieved using USP mesh screen (#35), and stored in the glass vials with
a rubber-lined cap for further studies.

Differential Scanning Calorimetry
A Perkin Elmer Hyper Differential Scanning Calorimeter (DSC) (Perkin Elmer Life and
Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) was used to analyze the samples.
This instrument was equipped with Pyris manager software (Shelton, CT, USA). Each sample in
this study weighed approximately 2–5 mg and was hermetically sealed in an aluminum pan. These
samples were heated from 20°C to 250°C at a linear heating rate of 10°C/min.

X-ray powder diffraction (XRD)
XRD was performed using a powder X-ray diffraction apparatus (Bruker AXS, Madison,
MI) using CuKα radiation, generator voltage at 40 kV, and current at 40 mA. The diffraction angles
were (2θ) of 5-40°at 2°/min scanning rate.

High-performance liquid chromatography (HPLC) chromatographic system and
conditions
A Waters HPLC, consisting of a Water 600 binary pump, Waters 2489 UV / detector, and
Waters 717plus autosampler (Waters Technologies Corporation, 34 Maple St., Milford, MA
0157), determined the drug content. A Phenomenex Luna® C18 reverse phase column (5 µm 100
Å, 250 x 4.6 mm) was used as the stationary phase. Empower 2 software was used to analyze the
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data. The mobile phase was water, methanol, and acetic acid (34:65:1 % v/v), and the UV detector
was set at 285 nm wavelength. The flow rate was maintained at 1.0 ml/min, and 20 μL was injected
from each sample. Drug content uniformity was assessed by dissolving accurately weighed CBZ
extrudates in methanol and subsequently quantified using the HPLC procedure outlined above.

In- vitro dissolution study
In vitro release studies (n=3) were carried out utilizing a Hanson SR8-plus™ dissolution
test station (Chatsworth, CA) operated at 100 RPM paddle speed with 900 ml of distilled water as
the dissolution medium, which was maintained at 37 + 0.5°C. CBZ extrudate samples were
accurately weighed (100 mg each) and added to the dissolution medium.

Statistical analysis
A full factorial design of experiment was performed using Design-Expert® software. To
compare between different formulations, statistical analysis was performed utilizing one-way
analysis of variance (ANOVA). A statistically significant difference was considered when P<0.05.
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RESULTS AND DISCUSSION
Typically, processing parameters are selected for HME through several iterative steps such
as materials thermal stability, extruder limitation and, of course, material properties (8). To ensure
the simplicity of the DOE design preliminary studies and literature reviews are required. In
addition, there are different steps should be follow to perform a DOE that are:
1. Define goals and variables.
2. Select a DOE.
3. Analysis the data.
4. Optimize output.
In the present study, CBZ was employed as a model drug and Soluplus® as the solubilizing
carrier matrix. Enhancing the solubility is the main goal of this formulation. Three different
variables will be evaluated screw speed, extrusion temperature and screw configuration. The most
important step in this study is to narrow down the range for each variable. For that, each variable
will be evaluated to find out the best way to narrow down its range.
The first variable in this study is extrusion temperature. HME is depends on the temperature
energy to melt the materials and in the presented study to produce a solid dispersion system. Chose
a temperature processing range usually depend on melting point, thermal stability, glass transition,
and desirable formulation form. Extrusion temperature provided using heating elements that
located inside the barrel of the extruder. Usually electrical heater bands are used. Most extruder is
equipped with different heating zone. This feature will assist in heat distribution and therefore heat
optimization. The temperature of the melting zone is usually higher than the conveying zone. The
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thermogravimetric (TGA) will help to determine the highest temperature can be used. The
extrusion used in this study can go up to 400°C. This wide range of temperature show the need to
narrow down this variable and therefore reduce the number of run. To do that, TGA studies were
performed on the materials used. The CBZ and Soluplus were evaluated for thermal stability at
high temperatures. TGA studies confirmed the thermal stability of Soluplus®, and CBZ under the
employed extrusion conditions with less than 1% drug degradation being observed when heated
up to 220 ⁰C (Figure 2-1). In this study, the formulations were processed below this temperature,
which eliminated the modest thermal instability issue. TGA also provide a great information that
cut down the initial high value from 400 to only 220⁰C.

Figure 2-1. TGA data for pre-extrusion for physical mixture and pure CBZ.
DSC study, showed the melting point of the CBZ, and glass transition of Soluplus®. In
figure 2-2, DSC thermogram indicate that CBZ has a characteristic melting endothermic peak at
192 ˚C, which is indicated the melting point of CBZ. Soluplus® was show a thermal peak around
65 ˚C that represent the glass transition temperature. CBZ has a narrow processing thermal range
between 192 to 220 ˚C. For that, Soluplus® well be a good carrier candidate with CBZ because it
will work as a plasticizer during the process.
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Figure 2-2 DSC thermogram of the pure CBZ and the pure Soluplus®
Furthermore, CBZ undergoes a polymorphic change when heated above 150⁰C, (9, 10)
producing non-pharmacological active forms. Additionally, it was reported that a homogeneous
solid dispersion could be obtained with Soluplus by using high temperature (more than 120 ⁰C).
However, a high extrusion temperature (above 160 ⁰C) may negatively disturb the solubilization
effect of Soluplus by making a cross linking reaction (4). For these reasons, the temperature limits
for this study are between 120 and 150 ⁰C. This relatively a narrow range of temperature that will
reduce the number of run and gave a good chance to find the optimum extrusion temperature using
DOE concept.
The second variable in this study is the screw speed. Screw speed will affect the resident
time, shearing force and extruder torque. That mean low screw speed will allow the formulation
to get more heat and low shearing force and vice versa. Formulation properties including viscosity,
melting point, and stability are factors to be consider to adjust the screw speed. For example, high
viscous materials will require low processing screw speed. Screw speed can be limited due to the
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extruder torque and pressure. The preliminary study indicated that molten Soluplus-CBZ matrix
exhibits high torque value when high screw speed is used (more than 150 RPM). On the other
hand, at low screw speed (less than 50 RPM) the extrudates became irregular in shape. This was
due to lower backpressure, which is an important factor in shaping the extrudates. Also, the
extruder acceptable pressure should not exceed 10% (4, 11) this limit the screw speed at 100 RBM.
These facts limit the screw speed in this study to speeds of 55-100 RPM.

Figure 2-3 Schematic diagram of the screw configurations (generated with twin Screw
Configurator, Version: 1.30 (8))
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The last variable in this study was the screw configuration. Twin-screw extruder has
different element types can be combined into several configuration. Screw configuration has
shown different effect of the final product properties (12, 13). In this study, two different screw
configuration were used (Figure 2-3). The first type of screw was with a low shearing screw design
utilizing two kneading zones. The second screw configuration with three kneading zones.
Kneading zones are to mix the molten materials and provide a high shear energy.
The next step in this study was to choose the best DOE design. The main goal of this study
is to find the simplest design that will provide all the information required. For DOE design, we
used screw configuration, screw speed, and extrusion temperature as the dependent variables, or
factors. In vitro CBZ release and drug content were used as the responses measured in this study.
The minimum level for each variable to apply the DOE concept is two levels. For that, a full two
level factorial design was chosen. The full two level factorial design used in this study can be used
to screen different factors (either categories or numeric) to find the most significant factor, also it
can be used to estimate the interaction between the factors. The DOE software suggested eight
different runs at different levels to determine the effect of each factor (Table 2-1). Each formulation
was extruded as shown in Table 2-1. Feeding rate was maintained constant at all times to eliminate
any other variations, and to maintain the residence time constant.
After extrusion, extrudates morphology status was confirmed to insure the production of a
solid dispersion system and the CBZ was converted into the amorphous status. Drug content and
drug release (at 30 min) were the responses analyzed for each formulation. DOE has the ability to
analyze several responses at once, but in this study, drug content and drug release were the most
important outputs for HME solid dispersion.
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Table 2-1. DOE formulations design model.
Formulation

CBZ (%)

Soluplus
(%)

Screw
configuration

Temperature
(°C)

Screw
speed
(RPM)

F1
F2
F3
F4
F5
F6
F7
F8

15
15
15
15
15
15
15
15

85
85
85
85
85
85
85
85

A
A
A
A
B
B
B
B

120
150
120
150
120
150
120
150

55
55
100
100
55
55
100
100

Differential scanning calorimetry (DSC) was performed to confirm the drug and polymer
miscibility and morphology status of CBZ (Figure 2-4). DSC data confirmed the miscibility of
CBZ with Soluplus®, as the melting peak disappeared after extrusion, which indicated that CBZ
was converted into amorphous form after extrusion. XRD data also confirmed the amorphous form
of CBZ in the extrudates, compared to the crystalline form of pure drug since no appearance of
characteristic peaks appeared in extrudates (Figure 2-5).
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Intensity

Figure 2-4. DSC data for pure CBZ, and formulations 1 - 8 (15:85 CBZ: Soluplus®).
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Figure 2-5. XRD data for pure CBZ, and formulations 1 - 8 (15:85 CBZ: Soluplus®).
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Extrudates’ drug content was analyzed by the HPLC data. Chromatographic method that
was used in this study validated as per the ICH and FDA guidelines. The linear calibration range
for the detection of CBZ was 5-200 μg/ml, with the coefficient of determination (R2) of 0.999.
The percentage relative standard deviation (% RSD) within replicates (n=3) was less than 2%,
demonstrating reproducibility of the method. All extrudates exhibited uniform drug distribution,
indicating that HME was able to produce a uniform solid dispersion. The change in screw speed
and extrusion temperature had no significant effect on drug content. However, content uniformity
was slightly affected by the screw configuration used. Using the second screw configuration
enhanced the content uniformity. This was due to using more kneading zones, which increased the
intensity of mixing.
Values of "Prob > F" less than 0.0500 indicates model terms are significant. In drug content
ANOVA analysis, there are no significant model terms. That mean, none of these changes were
statistically significant (Figure 2-6), so we completed this study using the drug release as the
primary response. In-vitro release data show that all formulations enhanced CBZ dissolution rates
when compared to dissolution rates of the pure drug (Figure 2-7). This enhancement was due to
the conversion of CBZ into the amorphous form. However, different drug release profiles were
observed with different extrudates. This show that processing parameters has shown a very
significant effect on the properties of the pharmaceutical formulation.
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Figure 2-6. Drug content ANOVA analysis (Design-Expert® software).
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Figure 2-7. In vitro release profiles of pure CBZ, and formulations 1 - 8 (15:85 CBZ:
Soluplus®).
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Figure 2-8. ANOVA analysis (Design-Expert® software).
Enhanced dissolution was observed, especially when processed with the three-kneadingzone screw configuration. These differences are statistically significant. In Figure 2-8, screw
configuration was shown the most significant influence on the drug release. Extrusion temperature
was also statistically significant. The interaction between the screw configuration and temperature
have a significant effect as well. These effects were due to the high mechanical energy applied
during the extrusion process, which resulted in higher energy and intense shearing rate. The second
screw configuration with three kneading zone in combination with temperature provides more
energy that leads to increase in the CBZ incorporation into the molten polymer and hence enhance
the drug release. Formulations (F6 and F8) processed with high temperature and three mixing
zones provided a superior amorphous dispersion over the other formulation. This is in agreement
with the DOE result. This show that processing parameters affect the quality of the extruded
product.
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DOE software can not only evaluating the data, but it can also use to test the model used
in the study. The model used in this study (2-level factorial design) was statistically significant
(The Model p-value 0.0027). This ensures that this model can be used to determine the significant
factors and to find the optimal formulation. That also indicates that there is no need to use a central
point for any parameter. Furthermore, DOE is capable of diagnosing the ANOVA data and
confirming these assumptions. In this study, three different diagnostic methods were used to verify
the model, normal plot, residuals (ei) versus run, and predicted versus actual methods. Normal plot
is a way to determine whether the error terms are normally distributed, the more liner, the more
normally distributed. The second methods were used to check the normality and data distribution
was the residuals (ei) versus run. Figure 2-9, show that all data were randomly scattered with no
trend. This validated the design and the model used, and indicate that there was no need for central
point runs. The last method was used to see if this model is best for formulation optimization or
not. Predicted versus actual indicated that this model has a high prediction percentage with low
error percentages.
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Figure 2-9. Diagnostics Plots.
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After validating the model, a design space can be produced to select the optimum
formulation. The optimum formulation in this study is the one with the highest drug release at 30
minutes. DOE show that the second screw configuration (with three mixing zones) was able to
produce a superior solid dispersion. The materials extruded are heated mainly by the heat generated
due to the shearing force of the rotating screw and the heat conducted from the heated barrel. For
that, the lowest possible temperature was selected to avoid any chance of converting the CBZ
polymorphs form. Screw speed did not show any significant effect; for this reason, the design
space was open to use any screw speed within the tested range (55-100 RPM). The best advantages
of using DOE software is the ability to select the required criteria for each parameter to build a
design space. DOE software is capable to suggest the design space and predict the response for
each suggested run (Figure 2-10).

Figure 2-10. Design space for optimum formulation.
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After selecting the criteria for each parameter DOE software suggests the final equation as
follows:
Response (R1) = +73.86641 + 0.20572 * speed - 4.58061E-003 * temp------- Eq 2.1
Subsequent to validating and finding the optimal formulation, three different run were
selected and extruded (Table 2-2). The Forecast error was used to determine the percentage error
between the predicted release value and the experiment value. The Forecast error for F9, F10, and
F11 were 3.16, 2.99 and 0.36 respectively. This shows that the full two level factorial design model
successfully predicted and enhanced the formulation with less percentage error. All formulations
were able to reach the main goal of this study, which is solubility enhancement of CBZ.

Table 2-2. Optimize formulations (Release at 30 minute).
Speed

Temperature

Predicted

Experiment

Forecast

RPM

°C

Release

Release

error

F9

91

125

88.45

85.29

3.16

F10

74

130

87.56

84.57

2.99

F11

64

135

87.67

88.03

0.36

Formulation
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CONCLUSION
Processing parameters show a significant effect on the final product properties. Using the
simplest factorial design allows the evaluation of each factor, and therefore the production of the
most ideal formulation. Use of the design of experiment concept reduces the cost and time
required, while giving a high percentage of success. A full 2-level factorial design was able to
evaluate processing parameters and obtain the most information in the fewest number of
experiment runs.
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CHAPTER 3
STABILITY-ENHANCED HOT-MELT EXTRUDED AMORPHOUS SOLID
DISPERSIONS VIA COMBINATIONS OF SOLUPLUS® AND HPMCASHF
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ABSTRACT
The aim of this study was to evaluate a novel combination of Soluplus® and hypromellose acetate
succinate (HPMCAS-HF) polymers for solubility enhancement as well as enhanced
physicochemical stability of the produced amorphous solid dispersions. This was accomplished by
converting the poorly water-soluble crystalline form of carbamazepine into a more soluble
amorphous form within the polymeric blends. Carbamazepine (CBZ), a Biopharmaceutics
Classification System class II active pharmaceutical ingredient (API) with multiple polymorphs,
was utilized as a model drug. Hot-melt extrusion (HME) processing was used to prepare solid
dispersions utilizing blends of polymers. Drug loading showed a significant effect on the
dissolution rate of CBZ in all of the tested ratios of Soluplus® and HPMCAS-HF. CBZ was
completely miscible in the polymeric blends of Soluplus® and HPMCAS-HF up to 40% drug
loading. The extrudates were characterized by differential scanning calorimetry (DSC), X-ray
diffraction (XRD), Fourier transform infrared (FTIR) spectroscopy and dissolution studies. DSC
and XRD data confirmed the formation of amorphous solid dispersions of CBZ in the polymeric
blends of Soluplus® and HPMCAS-HF. Drug loading and release of CBZ was increased with
Soluplus® (when used as the primary matrix polymer) when formulations contained Soluplus®
with 7–21% (w/w) HPMCAS-HF. In addition, this blend of polymers was found to be physically
and chemically stable at 40°C, 75% RH over 12 months without any dissolution rate changes.
KEY WORDS
Carbamazepine, hot-melt extrusion, HPMCAS-HF, Soluplus®, stability
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INTRODUCTION
Hot-melt extrusion (HME) has attracted considerable attention in the pharmaceutical
industry in the last couple of decades (1). HME has some advantages over other more traditional
processing techniques such as being a solvent free continuous process requiring fewer processing
steps (2). HME works as any solid dispersion system, that is, by converting the drug from its
crystalline form into its amorphous form or by the formation of a molecular dispersion/solid
solution (3). The amorphous form has more free energy than the crystalline lattice, which will lead
to increasing the dissolution rate (4). However, increasing the free energy of the materials will
affect the thermodynamic stability during storage (5). The inherent thermodynamic instability
tends to lead to a phenomenon known as recrystallization. Recrystallization will reduce the
dissolution rate and solubility of the active pharmaceutical ingredient (API), which leads to
decreased pharmacological delivery and efficacy (6). The lack of physical stability is one of the
main drawbacks of any amorphous dispersion (7). In the literature, many research papers showed
the feasibility of producing a solid dispersion using HME. However in the market, only a limited
number of extruded products can be found. The most commonly cited issue with solid dispersions
is the lack of physical stability (8). For this reason, the need of producing a stable solid dispersion
is as essential as the desired solubility enhancement.
Carbamazepine is an antiepileptic drug with poor water solubility (17.7 mg/L at 25°C, log
P value of 2.45) (9). It is considered a class II drug according to the Biopharmaceutical
Classiﬁcation System (BCS) which is characterized by low water solubility and high permeability.
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For oral administration, CBZ absorption is mainly dependent on the dissolution rate (10). A
correlation between the oral bioavailability and physical state of CBZ was revealed during an invivo pharmacokinetics study (11). It was suggested that formulation enhancements might result in
overall improved bioavailability (12). However, the formulation of CBZ for oral administration
faces challenges in addition to solubility enhancement. These challenges include a narrow
therapeutic window, high dosage requirement (100 mg/200 mg, BID or TID), and a narrow
thermally stable window for HME processing. CBZ has a high melting point (193˚C) and is
thermally stable only up to 220˚C. The high melting point makes CBZ a good candidate for HME.
However, the narrow thermally stable processing window poses certain challenges for the HME
formulation of CBZ. Additionally, CBZ can pose certain stability challenges post processing as
many polymorphs have been identified, and any of them could result from recrystallization after
HME processing (13).
To overcome the challenges of CBZ, Soluplus®, polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol graft copolymer, was selected as the primary carrier. It is an amphiphilic
polymer that can work as solubilizing agent as it forms micelles in solution. It is used to enhance
the solubility of poorly water soluble APIs by solid dispersion. The glass transition temperature
for Soluplus® is 70°C; this low glass transition temperature makes Soluplus® a good candidate for
extrusion of CBZ at relatively low temperatures; in fact, the polymer is very easily extruded.
Another advantage of Soluplus® is the low hygroscopicity of the polymer, which will help stabilize
the dispersion during storage. Based on the literature, Soluplus® can successfully enhance the
solubility of CBZ if less than 10% drug loading is used (14), while recrystallization and poor
dissolution were observed in one study when CBZ drug loading increased to be above 10% (15).
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However, high drug loading is required for CBZ as the therapeutic dose starts from 100 mg. For
this reason, another material with stabilizing effect was employed.
Another method to stabilize a solid dispersion is by using a carrier with a high glass
transition temperature (16). It was reported that the stabilized formulation can be achieved if the
formulation’s glass transition temperature is higher than 50°C compared to the storage temperature
(17). It was found that polymers with high glass transition temperature can potentially prevent
recrystallization by delayed kinetics (18). Thus, hypromellose acetate succinate (HPMCAS-HF)
polymer with a high glass transition temperature was selected as a secondary carrier with potential
stabilizing effects (19). HPMCAS-HF is not suitable for extrusion alone due to its high glass
transition temperature. However, blending HPMCAS-HF with Soluplus® facilitates its
extrudability in addition to increasing the formulations’ glass transition temperature, which
subsequently enhances physical stability.
In this study, the objective was to improve the solubility and physical stability of
carbamazepine (CBZ) using hot-melt extrusion technology. This was accomplished by converting
the poorly water-soluble crystalline form of carbamazepine to the more water soluble amorphous
form utilizing polymeric blends. Solubility enhancement was accomplished by producing an
amorphous solid dispersion utilizing Soluplus® as the solubilizing carrier, while physical stability
was enhanced by adding HPMCAS-HF as a stabilizing agent.
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MATERIALS AND METHODS
CBZ was purchased from Afine Chemicals Limited Zhejiang China, and was of high
purity. Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®)
was received as a generous gift from BASF Chemical Co. (Ludwigshafen, Germany).
Hypromellose Acetate Succinate (HPMCAS-HF) was supplied by Shin-Etsu Chemical Co. (Brand
name Shin-Etsu AQOAT). All other chemicals used were of analytical grade and obtained from
Fisher Scientific.
METHODS
Thermogravimetric analysis
A PerkinElmer Pyris 1 thermogravimetric analyzer (TGA) equipped with Pyris manager
software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., CT, USA) was utilized
to perform thermogravimetric analysis of samples. Each sample weighed three to five milligrams
and was heated from 20-250°C at a heating rate of 10°C/min.

Differential Scanning Calorimetry
A Perkin Elmer Hyper Differential Scanning Calorimeter (DSC) (Perkin Elmer Life and
Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) was used to analyze the samples.
This instrument was equipped with Pyris manager software (Shelton, CT, USA). Each sample in
this study weighed approximately 2–5 mg and was hermetically sealed in an aluminum pan. These
samples were heated from 20°C to 250°C at a linear heating rate of 10°C/min.
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Preparation of solid dispersions
The polymers were sieved using USP mesh screen (#35) and kept in an oven (40°C)
overnight to remove any residual moisture. The polymers were then blended in multiple ratios with
the API ( Table 3-1) using a twin shell V-blender (GlobePharma, Maxiblend®) at 25 rpm for
10 min. Each sample was subsequently melt extruded using a twin-screw extruder (16 mm Prism
EuroLab, ThermoFisher Scientific) under different processing conditions ( Table 3-1). After
extrusion, the melt extrudates were cooled to ambient temperature, milled using a comminuting
mill (Fitzpatrick, Model L1A), sieved using USP mesh screen (#35), and stored in the glass vials
with a rubber lined cap for further studies.
Table 3-1. Formulation composition on polymer ratio study of HPMCAS-HF and
Soluplus®

Formulation

Polymers ratio

HPMCAS-HF

Soluplus®

CBZ

(HPMCASHF:Soluplus®)

%

%

%

w/w

w/w

Extrusion condition

w/w

Temp
(°C)

Speed
(rpm)

F1

1:9

8

72

20

100-120

95

F2

2:8

16

64

20

110-120

85

F3

3:7

24

56

20

110-120

80

F4

4:6

32

48

20

110-120

80

F5

5:5

40

40

20

110-130

75

High-Performance Liquid Chromatography (HPLC) Chromatographic system and
conditions
The drug content was determined by a Waters high-performance liquid chromatography
(HPLC) consisting of a Water 600 binary pump, Waters 2489 UV/detector, and Waters
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717plus autosampler (Waters Technologies Corporation, 34 Maple St., Milford, MA
0157). A Phenomenex Luna® C18 reverse phase column (5 µm 100 Å, 250 x 4.6 mm) was used
as the stationary phase. Empower 2 software was used to analyze the data. The mobile phase was
water, methanol, and acetic acid (34:65:1 %v/v), and the UV detector was set at 285 nm
wavelength. The flow rate was maintained at 1.0 ml/min, and 20 μL was injected from each
sample. Drug content uniformity was assessed by dissolving accurately weighed CBZ extrudates
in 20 ml methanol, then transferring 1 ml into a 10 ml flask and adding 9 ml of methanol. These
1.5 ml samples were then centrifuged (Centrifuge Eppendorf 5415 R) for five minutes at 10000
RPM and 25°C, and subsequently quantified using the previously outlined HPLC procedure. Six
replicates were used for all of the assay studies. Dissolution study samples were centrifuged and
injected at a 20 μl injection volume.
X-ray powder diffraction (XRD)
XRD was performed using a powder X-ray diffraction apparatus (Bruker AXS, Madison,
MI) using CuKα radiation, generator voltage at 40 kV, and current at 40 mA. The diffraction angles
were (2θ) of 5-40°at 2°/min scanning rate.

Fourier transform infrared spectroscopy (FTIR)
FTIR studies were conducted on an Agilent Technologies Cary 660 (Santa Clara, CA.).
The bench was equipped with an ATR (Pike Technologies MIRacle ATR, Madison, WI) which
was fitted with a single bounce diamond coated ZnSe internal reflection element.
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In- vitro dissolution study
In vitro release studies (n=3) were carried out utilizing a Hanson SR8-plus™ dissolution
test station (Chatsworth, CA) operated at 100 RPM paddle speed with 900 ml of distilled water as
the dissolution medium, which was maintained at 37 + 0.5°C. CBZ extrudate samples were
accurately weighed (100 mg each) and added to the dissolution medium. Drug release profiles
were compared using the similarity factor (𝑓2 ), which can be calculated using the following
equation:
1

𝑓2 = 50 • log{[1 + (𝑛) ∑𝑛𝑡=1(𝑅𝑡 − 𝑇𝑡 )2 ]−0.5 • 100}(20)------------------- Eq. 3-1
where Rt and Tt are the cumulative percentage dissolved at each time point n of the reference and
test product, respectively. In accord with the FDA guidance for industry, two dissolution profiles
are considered similar or equivalent when the value of similarity factor (f2) is greater than 50.

Stability Study
Two methods were used to compare the formulations after 12 months of storage. The first
utilized XRD to show the morphology changes with time. The second involved comparing the in
vitro release at different storage time intervals to show the difference between each formulation
with respect to time. Extrudate samples were stored in a stability chamber at 40°C and 75% RH.
Stability studies were performed after 3, 6, and 12 months and samples were tested for crystalline
content by XRD, chemical stability by HPLC, and in-vitro release profile comparisons.
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RESULTS AND DISCUSSION
TGA
The drug and excipients were evaluated for thermal stability at high temperatures. TGA
studies revealed that Soluplus®, HPMCAS-HF, and CBZ were stable under the employed extrusion
conditions with no trace of any drug degradation being observed when heated to 190⁰C (Figure 31). In this study, the formulations were processed below this temperature, which eliminated the
modest thermal instability issue.

Figure 3-1. TGA data for pre-extrusion of formulation F1, F2, F3, F4, F5 and pure CBZ.
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Polymer ratios
Different polymer ratios between HPMCAS-HF and Soluplus® were studied to investigate
the effect of HPMCAS-HF on extrudability and dissolution profiles. Formulations with different
ratios of HPMCAS-HF to Soluplus®, at a fixed drug loading of 20% ( Table 3-1), were processed
to determine their HME feasibility and dissolution rate enhancement. All of the extruded
formulations demonstrated a higher dissolution rate relative to the pure drug. The dissolution rate
of CBZ was enhanced with increasing concentrations of Soluplus®, indicating that Soluplus®
played a key role in the dissolution enhancement of the drug. The addition of HPMCAS-HF was
associated with limited extrudability and decreased drug release (Figure 3-2). It was determined
that HPMCAS-HF can be extruded with Soluplus® up to a 1:1 ratio (formulation F5). At higher
drug loading excessively high pressures and torque values were observed. At the same time, it was
observed that an increase in HPMCAS-HF content was detrimental to the dissolution rate when it
was higher than 30%. Figure 3-2 indicates that there was no effect from the addition of HPMCASHF on drug dissolution when added up to 30% (F3). These results indicated that 3:7 polymers ratio
(HPMCAS-HF:Soluplus) was the maximum extrudable ratio with drug release enhancement.
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Figure 3-2. In vitro release studies for different polymers ratios
Drug loadings
The influence of drug loading was evaluated in order to reach an optimized loading in terms
of both extrudability and dissolution rate. A polymer ratio of 3:7 (F3 in Table 3-1) was selected
to change the drug loading to 10%, 20%, 30%, 35% and 40% as the polymer ratio studies indicated
that HPMCAS-HF presented no effect on drug release if used up to that ratio. The extrusion
parameters were kept constant for all of the formulations to eliminate any other interference or
changes. It was determined that the drug loading demonstrated a significant effect on the
dissolution rate of CBZ with Soluplus® and HPMCAS-HF. The DSC studies show that the CBZ
melting peak disappeared in the extrudates indicating that CBZ was completely miscible in the
polymeric blends of Soluplus® and HPMCAS-HF up to 40% drug loading (Figure 3-3A). The DSC
thermograms indicate that molten formulations were able to depress the melting point of CBZ and
produce an amorphous solid dispersion at the employed extrusion conditions. Additionally, this
confirms that dissolution rate enhancement for drug loading was below 40%.
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Figure 3-3. Drug loading study on formulation F3 at polymer ratio of 3:7 (HPMCAS-HF:
Soluplus®). A) DSC data on miscibility study for drug loading of 20, 30, 35, 40 and 45%
(CBZ w/w); B) in vitro drug release profiles for F3 at different drug loadings.
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This enhancement is due primarily to the presence of the amorphous form of CBZ after extrusion.
Moreover, at up to 35% drug loading the extrusion process was still producing transparent
extrudates and amorphous CBZ, compared to the opaque crystalline CBZ which was observed at
higher levels, which suggests a phase separation at higher drug loading. Furthermore, in-vitro
release studies showed that each drug loading produced a different release profile (Figure 3-3B).
It was observed that above 35% drug loading a significant dissolution rate change was observed.
At the same time, 35% drug loading demonstrated a delay in drug released when compared to
lower drug loadings. This delay may due to residual crystalline CBZ present with the amorphous
form that cannot be detected by the DSC. This drug loading limitation was because of hydrophilic
and hydrophobic balance as well as the dispersibility limitation in the molten polymers, which is
in agreement with previous literature reports (21). Moreover, for any solid dispersion, drug loading
significantly affects the interplay between the characteristics of API (melting temperature, antiplasticizing or plasticizing effect), processing conditions employed and the relative melt viscosities
of the polymeric carrier. In this study, a 16 mm twin screw extruder with three mixing zones was
used. The number of mixing zones and configuration was selected based on preliminary studies.
This screw configuration imparted a high degree of shearing force and intense mixing below
150°C. This reduced the chance that CBZ would exhibit polymorphic changes from form III to
polymorph I, which has lower pharmacological effect and can be produced by heating polymorph
III above 150°C (22). Moreover, solid dispersion produced by HME can be predicted by the Flory–
Huggins lattice theory for miscibility between the polymer and API. This theory indicates that the
thermodynamics (entropy of mixing) is dependent on the ratio between the carrier and the polymer.
The CBZ-polymer miscibility will depend on its ratio and extrusion processing parameters. This
is consistent with a reported miscibility study between CBZ and Soluplus® (23). It was found that
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Soluplus® has limited dispersibility and miscibility with CBZ according to CBZ content percentage
and the temperature used. For this reason, 30% drug loading was used as the optimized drug
loading, however, which is higher than the drug loadings employed in previous publications by 3fold ((14),(23)). Therefore, the stability study was conducted by using minimum and maximum
HPMCAC-HF ratios to investigate the recrystallization inhibitory effect of HPMCAS-HF (Table
3-2). A control formulation consisting of Soluplus® (70%) and CBZ (30%) without HPMCAS-HF
was used to show the influence of HPMCAS-HF on stability. The drug loading was kept as high
as 30% to prove the stability issues associated with the higher drug loading. All extrusion
parameters were held constant to eliminate other factors except the formulation composition.
Table 3-2. Final formulation composition and processing conditions for stability study (A
with no HPMCAS-HF, B has low HPMCAS-HF ratio, and C has high HPMCAS-HF ratio).
CBZ

HPMCAS-HF

Soluplus®

%, w/w

%, w/w

%, w/w

Temp/ ℃

Speed/RPM

A

30

0

70

110-120

80

B

30

7

63

110-120

80

C

30

21

49

110-120

80

Formulation

Extrusion Conditions

Drug Content
After extrusion, each formulation was analyzed for drug content and content uniformity
using HPLC. All formulations were in the acceptable range according to FDA guidelines and the
United States Pharmacopeia for carbamazepine tablet. Moreover, drug content was compared
between fresh extrudates and after storage (Figure 3-4). It was found that before and after storage,
the content of CBZ in all extrudates ranged between 99.01 and 103.04% (Figure 3-4). That
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indicated that CBZ was chemically stable with no trace of degradation or weight loss after storage
for 12 months (at 40°C and 75% RH). Additionally, each formulation demonstrated uniform drug
content with relative standard deviation ranging between 1.05 and 2.86% for fresh extrudates and
after storage for 12 months, respectively. This indicated that the HME processing conditions
imparted excellent content uniformity with high chemical stability.

Figure 3-4. Drug content of formulation A (30:70 CBZ: Soluplus®), B (30:7:63 CBZ:
HPMCAS-HF: Soluplus®) and C (30:21:49 CBZ: HPMCAS-HF: Soluplus®) extrudates at
day 1 and 12 months after stored at 40ºC/75% RH.

DSC
Differential scanning calorimetry (DSC) was performed to confirm drug-polymer
miscibility and the amorphous nature of extrudates. The DSC thermograms showed that pure CBZ
was characterized by a single, sharp melting endotherm peak at 192.9°C (Figure 3-5). Miscibility
was determined by scanning multiple samples with different drug loadings. The DSC thermograms
(Figure 3-3A) showed that the maximum CBZ miscibility with Soluplus® and HPMCAS-HF was
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found at 40% drug loading. Samples with drug loading higher than 40% had CBZ crystalline
melting peaks reappearing (formulation F3-45%). The physical mixtures showed a thermal peak
for CBZ between 188-190°C, while the extrudates showed no thermal peak for CBZ (Figure 3-5).
This indicates that CBZ was solubilized and converted into the amorphous form in the polymer
melt after extrusion.

Figure 3-5. DSC data for pure CBZ, formulation A (30:70 CBZ: Soluplus®), B (30:7:63
CBZ: HPMCAS-HF: Soluplus®) and C (30:21:49 CBZ: HPMCAS-HF: Soluplus®) with
their corresponding physical mixtures.
XRD
XRD was used to study the morphology and physical stability of CBZ in the extrudates.
Carbamazepine has characteristic peaks at 2θ = 16, 18, and 27° (Figure 3-6). The examined
extrudates showed no traces of crystallinity as the characteristic peaks disappeared completely
from the obtained diffractograms apparent when analyzing the pure drug (Figure 3-6), while the
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corresponding physical mixtures did show the characteristic crystalline peaks from CBZ. XRD
and DSC data confirmed that HME produces a solid dispersion system wherein the crystalline
form of CBZ was converted to its amorphous form.

Figure 3-6. XRD data for pure CBZ, formulation A (30:70 CBZ: Soluplus®), B (30:7:63
CBZ:HPMCAS-HF:Soluplus®) and C (30:21:49 CBZ:HPMCAS-HF:Soluplus®) with their
corresponding physical mixtures.
In vitro release
CBZ release profiles from the extrudates were compared with pure CBZ and corresponding
CBZ/polymers physical mixtures. The results are shown as percent drug dissolved. Due to poor
solubility and wettability, the dissolution of pure CBZ was very low exhibiting less than 20%
dissolution after 120 min. The physical mixtures showed slight release improvement when
compared to the pure drug (Figure 3-7). All of the extruded formulations demonstrated rapid and
extensive CBZ release compared with their corresponding physical mixture with more than 80%
drug release within 20 minutes. More than 97% drug released within 15 min for formulation A,
while its physical mixture showed less than 8% release in 15 min. By comparing the extrudate
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release profiles with their corresponding physical mixture, it is evident that HME processing was
successfully able to produce a formulation with an enhanced dissolution rate. This was attributed
to the production of amorphous CBZ in addition to the hydrophilic properties of the polymer.

Figure 3-7. In vitro release profiles of pure CBZ, formulation A (30:70 CBZ: Soluplus®), B
(30:7:63 CBZ:HPMCAS-HF:Soluplus®) and C (30:21:49 CBZ:HPMCAS-HF:Soluplus®)
with their corresponding physical mixtures.

FTIR
FTIR spectra (Figure 3-8) for pure CBZ demonstrated the characteristic peaks of crystal
CBZ form III at wavenumbers 3461 (15). This peak was also shown in the physical mixtures of
formulation A, B and C and suggests that there was no intermolecular interaction between CBZ
and the polymers when physically mixed together. Furthermore, the hydrogen bond formation that
was suggested in the literature (25) between CBZ and Soluplus® was observed at 1033 cm−1.
However, this peak broadening became more pronounced with increasing concentrations of
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HPMCAS-HF in formulation B and further in formulation C. The absorbance area at wavenumber
1033 cm−1 was increased 0.521, 0.668, and 1.20 for formulation A, B, and C, respectively. This
increase indicated that the intensity of the hydrogen bond is increased by adding HPMCAS-HF.
Moreover, the characteristic peak for N-H stretching vibrations of a primary amide group of CBZ
at 3154 cm−1 was shifted and replaced with a broader peak at 3158 cm−1 in the C extrudates. This
potentially indicated the formation of hydrogen bonding with the hydroxyl group of HPMCASHF. This shifting became more pronounced by increasing the concentration of HPMCAS-HF. The
CBZ carbonyl peak at 1673 cm−1exhibited the same broadening and shifting to 1676 cm−1 with
increasing HPMCAS-HF ratios (26, 27). The hydrogen bond formation should work
synergistically with Soluplus® to enhance the solubility and stability of the formulations.
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Figure 3-8. FTIR spectra of pure CBZ, fresh extrudates for formulation A (30:70 CBZ:
Soluplus®), B (30:7:63 CBZ:HPMCAS-HF:Soluplus®), C (30:21:49 CBZ:HPMCASHF:Soluplus®), and their corresponding physical mixture.
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Stability study
The chemical and thermal stability of CBZ post extrusion were investigated. According to
preliminary screening studies, it was found that HPMCAS-HF can be extruded with Soluplus® up
to 30% without any dissolution rate hindrance. Therefore, lead formulations were chosen based on
the extrudability and the in vitro dissolution results (Table 3-2).
Formulation A (no HPMCAS-HF added) demonstrated retarded drug release profiles with
an increase in storage time from day 1 to months 3, 6 and 12 (Figure 3-9A). This decrease was due
to recrystallization of CBZ during storage, which was confirmed by XRD and FTIR analysis. As
shown by the XRD results (Figure 3-10A), the characteristic peaks of crystal CBZ had begun to
reappear at months 3, 6, and 12. After storage for 12 months (at 40 ℃/75% RH), formulation A
showed the same crystal peaks of CBZ at 3461 cm-1 as shown in FTIR results. These results are in
agreement with previous literature reports (23). It indicates that only Soluplus® cannot keep
amorphous CBZ physically stable in higher drug loading for the duration of the stability studies.
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A

B

C

Figure 3-9. In vitro release profiles of extrudates stored at 40°C/75% RH. A) Formulation
A; B) Formulation B; C) Formulation C.
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A

B

C

Figure 3-10. XRD data for physical mixtures, fresh extrudates and extrudates after 3, 6 and
12 months storage at 40°C/75%. A) Formulation A (30:70 CBZ: Soluplus®); B:
Formulation B (30:7:63 CBZ:HPMCAS-HF:Soluplus®); C) Formulation C (30:21:49
CBZ:HPMCAS-HF:Soluplus®).
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However, for both formulations B and C, as shown in Figure 3-9B and 9C, comparable
release profiles were observed over storage times of 0, 3, 6, and 12 months. This clearly indicates
that these blends were able to enhance CBZ release without remarkable changes even after the
long term storage of 12 months. The similarity factor values (f2) for release profiles between fresh
and 12 months extrudates were 78.8 and 75.3 for formulation B and C, respectively, which are
considered very similar release profiles according to the FDA guidelines. XRD data confirmed
that both formulations B and C did not show any sign of recrystallization or morphology change
after a storage time of 12 months (Figure 3-10B and 10C). Likewise, FTIR data indicated the
presence of the amorphous form of CBZ after storage for formulations B and C.
According to these studies, it was determined that adding HPMCAS-HF in Soluplus® based
solid dispersions were able to physically stabilize the amorphous form of high loading CBZ in the
extrudates. This stabilization was due to the high Tg and low hygroscopic nature of HPMCASHF. Low hygroscopicity will prevent moisture uptake, which is a significant factor for
recrystallization. Specific grades of HPMCAS are determined by the ratio between acetyl and
succinoyl groups (24). In this study, we used HPMCAS-HF that has the lowest level of succinoyl
groups and highest acetyl substituent level compared with other HPMCAS grades. It was reported
that succinoyl substituent level in HPMCAS polymers induce strong affinity with the hydrophobic
drug surface, leading to crystal growth inhibition of the API (25). This low level of succinoyl
groups in HPMCAS-HF decreased the recrystallization of CBZ by increasing the hydrophobic
interaction with CBZ, which will reduce the moisture uptake and subsequently inhibit the
recrystallization (26). Moreover, the high glass transition temperature of HPMCAS-HF as well as
the hydrophobic nature will suppress the crystallization growth of CBZ by inhibiting the molecular
mobility within the solid dispersion. Furthermore, FTIR data suggested that adding HPMCAS-HF
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increased the intensity of hydrogen bonding formation with CBZ. This H-bond formation may
physically stabilize CBZ by inhibiting the mobilization of CBZ within the solid dispersion (Figure
3-11). On the contrary, Soluplus® alone (formulation A) was not able to maintain the dissolution
enhancement or the amorphous morphology of high loaded CBZ. HPMCAS-HF did not alter the
solubility enhancement if used in low percentages between 7-21 %. This ratio demonstrated a
promising blend to be used with HME to enhance the solubility and stability of CBZ.

Figure 3-11. HPMCAS-HF and carbamazepine chemical structure shown hydrogen bond
donor and acceptor.
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CONCLUSION
This work investigated a new combination of polymers that can be used as a simple and
effective carrier for hot-melt extrusion processes to enhance solubility and inhibit recrystallization
for up to 12 months at accelerated storage. Soluplus® was able to enhance the dissolution rate of
CBZ and adding HPMCAS-HF increased the stability due to its high Tg and low hygroscopic
nature. Soluplus® extrudability enhanced the processing ability of this system and potentially other
blended matrices as well. This work showed the effect of multiple factors such as polymer
selection, different polymers ratios, and drug loading on drug solubility and stability. These
findings emphasize the importance of selecting an appropriate blend of carriers in order to obtain
a desired stable formulation with an enhanced release profile. Soluplus® as the primary matrix
polymer with HPMCAS-HF, processed by HME, demonstrates a potentially promising carrier to
produce physically stable formulations with solubility enhancement and no changes in physical
and chemical status after 12-month storage at 40°C/75% RH.

“Reprinted from AAPS PharmSciTech, Alshahrani, Saad M., et al. "Stability-enhanced
Hot-melt Extruded Amorphous Solid Dispersions via Combinations of Soluplus® and
HPMCAS-HF." (2015): 1-11, with permission from Springer (3640031308162).”
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CHAPTER 4
INFLUENCE OF DEGASSING ON HOT-MELT EXTRUSION PROCESS
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ABSTRACT
The present study aimed to evaluate the effect of degassing on an extrusion process, with
respect to extrudate quality and drug release properties. Processed formulations were extruded
with and without a degassing vent port at various locations along the barrel. All the experiments
were performed under constant processing temperature, feeding rate, and screw speed. During the
extrusion process, torque and pressure were monitored and recorded. The degassing process was
beneficial when used over a conveying section after a mixing section. This is attributed to the large
surface area available on the conveying elements, which minimizes the internal volume of the
processed material, thereby facilitating the escape of entrapped gases. Degassing enhanced the
homogeneity, physical appearance, and drug release properties of all the formulations.
Furthermore, the degassing process also enhanced the cross-sectional uniformity of the extruded
material, which is beneficial for visual monitoring during processing. Degassing considerably
reduced the post-extrusion moisture content of Formula D3, which contains the highly hygroscopic
polymer Kollidon® 17 PF, suggesting that the greatest influence of this process is on hygroscopic
materials. The reduction in post-extrusion moisture content resulting from the inclusion of a
degassing vent port, reduced fluctuations in the values of in-line monitoring parameters such as
pressure and torque. Employing a degassing unit during hot-melt extrusion processing could help
increase process efficacy and product quality.
Keywords:
Hot-melt extrusion (HME), Degassing, Carbamazepine, Chemical imaging.
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INTRODUCTION
Hot-melt extrusion (HME) is a well-investigated technology in both the food and plastic
industries and involves a continuous process where molten materials under elevated temperature
and pressure, are pumped along a rotating screw and out through an orifice (1). Over the last thirty
years, HME has emerged as a promising cost-effective technology for the pharmaceutical industry.
The advantages of this process are that it has high throughput and relatively few processing steps
compared to more conventional pharmaceutical processing technologies, and is both solvent free
and potentially continuous (2). Currently, HME is widely used in the production of solid
dispersions and controlled release formulations (3). Various dosage forms, such as pellets, tablets,
and mucoadhesive films for transmucosal products, can be easily prepared from hot-melt
extrudates (3). However, the potential for HME applications in pharmaceutical research and
development has not yet been fully realized, mainly owing to the complexity of HME design and
the non-Newtonian behavior of the extruded materials (4). This makes it somewhat difficult to
predict the behavior of materials processed by HME using mathematical modeling (5).
HME technology has been adopted primarily from the plastics industry, and therefore
monitoring of the process and product quality may require adaptation to the requirements of the
pharmaceutical industry. For example, the materials used in the production of plastic or food
products are usually less valuable and/or sensitive than pharmaceutical products. In addition, the
physicochemical properties of pharmaceutical constituents may not require the same
considerations as those processed in other industries (i.e. water solubility, molecular weight, polar
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surface area, partition coefficient, etc.). As a continuous process, the starting materials and
processing parameters have important role in controlling the quality of the hot-melt extrudates (2).
Several reports have illustrated the significant impact of processing parameters on the
physicochemical properties of the extruded drug (6). In a study presented by Liu, Wang et al. 2010,
demonstrated the influence of extrusion temperature, screw speed, and residence time on the
dissolution rate(7). The dissolution rate was significantly increased with increasing extrusion
temperature and screw speed, an observation that can be explained by the enhancement of
distributive mixing.
The processing parameters that are of primary importance to the pharmaceutical industry
are temperature, feeding rate, and screw speed; however, additional factors that may also affect
both the process and the final product include degassing, torque, and pressure (8). Effective
degassing has been shown to have multiple effects on products in the plastic and food industries,
including an increase in the free volume, reduction in the residual moisture content, improvements
in odor, changes in the visual appearance, alterations in mechanical properties, prevention of
bubbling or foaming, and homogeneity of mixing (9). Kohlgrüber in 2012 demonstrated that
proper degassing could easily be attained by changing the number, location, and geometry of the
degassing vent port openings. Although the pharmaceutical literature strongly suggests that there
is a definite need to investigate the influences of screw torque and degassing (10), pertinent studies
relating to the impact of the degassing process on pharmaceutical applications are limited.
Degassing is generally regarded in the pharmaceutical industry as merely an additional step in the
manufacturing process (5). In the production of plastics and food, degassing has been intensely
investigated and several studies have shown it to have a considerable influence on the properties
of the final product (11). Multiple protocols have been developed to enhance the degassing
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process, including the use of vacuum equipment, addition of a stripping agent, and designing
screws specifically for degassing (12).
Degassing or venting is the process of removing gas and other volatile substance from
extruded materials (11) and should be considered one of the most important steps for any extrusion
processes. Generally, gases may arise from the air trapped during the feeding process, or from the
processed materials (13). Materials extruded with either polymers or active pharmaceutical
ingredients (API) can have air trapped in the pores or adherent to their surfaces (5). The entrapped
molecules may affect other processing parameters as well as the quality of the product. Under
conditions of elevated temperature and pressure, melted materials are compressed and
consequently, degassing is necessary to remove any residual moisture, air, polymer monomers,
oligomers, solvents, reaction products, and decomposed materials, which could interfere if
released during the extrusion process.
The main objective of this study was to determine the influence of extrusion degassing on
the properties of the extrudate such as dissolution rate, physical stability, and chemical stability as
well as to monitor other parameters while evaluating the visible effects on the product. In this
study, the effect of a vent port open to the atmosphere, with a large opening to release gas while
retaining molten materials was evaluated.
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MATERIALS AND METHODS
MATERIALS
Carbamazepine was purchased from Afine Chemicals Limited, Zhejiang, China.
Polyvinylpyrrolidone (Kollidon® 17 PF) was received as a gift sample from BASF Chemical Co.
(Ludwigshafen, Germany). Hydroxypropylcellulose (Klucel™ ELF) was received as a gift sample
from Ashland Inc (Wilmington, DW 19808 USA). All other chemicals used were of analytical
grade and obtained from Fisher Scientific (Fair Lawn, NJ 07410 USA).
METHODS
Thermal Characterization Studies
Thermogravimetric Analysis
A Perkin Elmer Pyris 1 thermogravimetric analyzer (TGA) equipped with Pyris manager software
(PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA) was used for
thermogravimetric analyses of the samples. Each sample was weighed and heated from 20-220°C
at a heating rate of 10°C/min under an inert nitrogen atmosphere and monitored for the percent
weight loss with temperature increase.
Differential Scanning Calorimetry
A Perkin Elmer Diamond Differential Scanning Calorimeter (DSC) (Perkin Elmer Life and
Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) equipped with Pyris manager
software (Shelton, CT, USA) was used to perform polymer-drug miscibility studies. Each test
formulation in this study was weighed (approximately 2–5 mg) and was hermetically sealed in an
aluminum pan. The samples were then heated from 20°C to 220°C at a linear heating rate of
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10°C/min under an inert nitrogen atmosphere. The extrudates were also evaluated in a similar
manner to assess the morphology of the API.
Moisture content
Moisture content was examined by measuring loss on drying (LOD) using a
halogen moisture analyzer balance (MB45 moisture analyzer, Ohaus, USA). Each formulation was
analyzed before and after extrusion. The percentage of moisture was estimated by drying five to
eight grams of each mixture at 105°C for 15 min.
Non-Thermal Characterization Studies
Chromatography system and conditions

The drug content was determined on a Waters high-performance liquid chromatography
(HPLC) system consisting of a Water 600 binary pump, Waters 2489 UV/ detector, and Waters
717plus autosampler (Waters Technologies Corporation, 34 Maple St., Milford, MA 0157).
Empower 2 software was used to analyze the data. A Phenomenex Luna® C18 reverse phase
column (5 µm 100 Å, 250 × 4.6 mm) was used as the stationary phase. The mobile phase was
water, methanol, and acetic acid (34:65:1% v/v/v), and the UV detector was set at a wavelength of
285 nm. The flow rate was maintained at 1.0 mL/min, and 20 μL of each sample was injected. The
uniformity of the drug content was assessed by dissolving a weighed quantity of the carbamazepine
extrudate in methanol with subsequent analysis by the HPLC procedure outlined above. All studies
were performed in triplicate. Samples from the dissolution studies (section 2.2.2.3) were filtered
and 20 μL was injected for analysis by the same protocol.
Fourier transform infrared spectroscopy (FTIR) and Chemical imaging
Mid-infrared spectra from 4000-650 cm-1were collected on an FTIR (Agilent
Technologies, Cary 660 & 620IR) apparatus equipped with a sampling accessory (MIRacle ATR,
Pike Technologies), fitted with a single bounce diamond coated ZnSe internal reflection element.
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Chemical images were collected using an infrared microscope, which was equipped with a Ge
micro ATR. The spectra were analyzed using Agilent’s software suite (Resolutions Pro Version
5.2.0).
In-vitro dissolution study
Extruded samples were accurately weighed (100 mg carbamazepine) and put into
hydroxypropyl methylcellulose (HPMC) capsules. In-vitro release studies (n=3) were carried out
at 37 ± 0.5°C using a Hanson SR8-plus™ dissolution test station (Chatsworth, CA) operated at
100 rpm paddle speed with 900 ml of distilled water as the dissolution medium (14). Samples were
collected at 10-, 20-, 30-, 45-, 60-, 90-, and 120-min intervals and were then filtered and analyzed
using the HPLC method described above.
Stability Study
Extruded samples were stored in a stability chamber at 40°C and 75% relative humidity
(RH) for three months. Stability studies were then performed to test the crystalline content (using
DSC), chemical stability (HPLC), and in-vitro release parameters. The drug release profiles were
compared using a mathematical approach for two factors, a similarity factor (f2) and a dissimilarity
factor (f1). Both can be calculated using the following equations:
𝑛

𝑓1 = {[∑

𝑛

(𝑅𝑡 − 𝑇𝑡 )]/[∑

𝑡=1

𝑓2 = 50 • log{[1 + (1⁄𝑛) ∑

𝑛

𝑅𝑡 ]} • 100

𝑡=1

(𝑅𝑡 − 𝑇𝑡 )2 ]−0.5 • 100}

𝑡=1

The dissolution profiles can be considered similar when the value of the similarity factor (f2) is
greater than 50 and the dissimilarity factor (f1) is less than 15 (15).
Preparation of solid dispersions
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The polymers Kollidon® 17 PF and Klucel™ ELF were sieved through a USP mesh screen
(#35) and stored in an oven (40°C) overnight to remove any residual moisture. They were then
blended

with

carbamazepine

(Table

4-1)

using

a

twin

shell

V-blender

(GlobePharma, Maxiblend®) at 25 rpm for 10 min. Each formulation was subsequently melt
extruded using a co-rotating twin-screw extruder (16 mm Prism EuroLab, ThermoFisher
Scientific; Standard screw design configuration, Figure 4-1a) employing the same processing
conditions for each polymer (temperature, screw speed, and feeding rate; Table 4-1). In this study,
the vent port used has an open to the atmosphere to allow the gases to escape outside the extruder
without using any vacuum device (Figure 4-1b). This insert has an opposite direction open for gas
releasing (75 mm) at the same time its design to prevent the flow of melted material outside the
extruder as well as to not block the opening itself. After processing, the extrudates were cooled to
ambient temperature and stored in sealed glass vials for further investigation.
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Table 4-1. Formulation processing conditions.
Formul
ation

A0

A1

A2

A3

A-PM
D0
D1
D2
D3
D-PM

Poly
mer
Kollid
on®
17 PF
Kollid
on®
17 PF
Kollid
on®
17 PF
Kollid
on®
17 PF
Kollid
on®
17 PF
Klucel
™ ELF
Klucel
™ ELF
Klucel
™ ELF
Klucel
™ ELF
Klucel
™ ELF

CBZ
%
(w/
w)

Polym
er%
(w/w)

Vent
port

Torque
%

25

75

None

19.89
(7.48)

2.35
(2.31)

25

75

Zone
4

25.52
(6.02)

25

75

Zone
6

25

75

25

Drug
Content
%

Screw
speed
(rpm)

Temper
ature
(°C)

6.21
(1.28)

91.79
(6.84)

100

145

2.47
(0.03)

2.48
(0.74)

94.84
(4.99)

100

145

23.91
(2.69)

2.52
(0.00)

1.02
(0.84)

99.38
(3.65)

100

145

Zone
9

20.40
(1.38)

2.01
(0.00)

0.73
(0.21)

102.72
(2.47)

100

145

75

NA

NA

NA

7.64
(0.92)

101.31
(2.61)

NA

NA

25

75

None

2 (0)

3.32 (2.4)

100

140

25

75

100

140

25

75

100

140

25

75

100

140

25

75

NA

NA

Zone
4
Zone
6
Zone
9

46.61
(4.22)
73.59
(2.30)
73.76
(1.67)
55.95
(1.56)

NA

NA

Pressure Moisture
(Bar)
Content %

2 (0)
2 (0)

2.71
(2.08)
2.34
(1.29)

2 (0)

1.8 (0.89)

NA

3.45
(0.77)

Parentheses represent relative standard deviation, PM- physical mixture.

86

91.41
(1.9)
93.14
(1.51)
95.41
(1.44)
99.05
(1.12)
99.64
(1.72)

Figure 4-1. a) Schematic representation of screw design configuration of 16-mm extruder
and b) Vent port.
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RESULTS AND DISCUSSION
Thermogravimetric Analysis (TGA)
TGA studies were performed on the carbamazepine formulation with Kollidon® 17 PF and
KlucelTM ELF physical mixtures. TGA thermograms showed that each formulation was thermally
stable when heated from 20°C to 220°C, which was above the extrusion temperature (Figure 4-2).
This data indicated that the formulations would not undergo degradation at the temperatures
employed during the extrusion process.

Figure 4-2. TGA data for pre-extrusion for different polymers and pure CBZ.
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Differential Scanning Calorimetry (DSC)
DSC thermograms confirmed the presence of the amorphous form of carbamazepine in all
the freshly extruded formulations. Figure 4-3 illustrates the lack of the thermal events associated
with the melting of crystalline carbamazepine (193°C) and demonstrates that carbamazepine was
completely miscible at drug loading used in each polymer. DSC data indicated that CBZ is miscible
with Kollidon® 17 PF and Klucel™ ELF, which were confirmed in the literature (16-18).
Additionally, the DSC data shows that the degassing process had no effect on the morphology of
carbamazepine.

Figure 4-3. DSC data for pure CBZ, and all the extruded formulations.
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Moisture content
The moisture content of each formulation was measured to evaluate the impact of the
degassing step on the moisture content of the final product. Prior to extrusion, the moisture content
of the Kollidon® 17 PF and KlucelTM ELF mixtures was approximately 7.64% and 3.45%,
respectively. This relatively high moisture content demonstrates that overnight oven drying was
ineffective in terms of removing residual moisture, and that this commonly employed, preparatory
step is unnecessary. This proved to be especially true for highly hygroscopic polymers including
Kollidon® 17 PF. Furthermore, the formulations containing Kollidon® 17 PF and KlucelTM ELF
extruded without the degassing step had a moisture content of 6.21% and 3.32%, respectively,
after extrusion. These results demonstrate that the extrusion process (without a vent port) can
remove a small portion of the adsorbed moisture content either through the feeding hopper, the die
or during the post process cooling. In contrast, when a vent port was included, the moisture content
of the extrudates was decreased to a mere 0.73% (Table 4-1) and progressively decreased as the
vent port was moved further downstream (i.e. toward the die of the extruder). As shown in Table
4-1, the moisture content significantly decreased for both polymers when the vent port was located
at zone nine (Formulation A3 and D3). This could be attributed to the pressure differences inside
the barrel at each location. In any screw extruder, after the feeding section the materials are moved
inside the barrel by the rotation of the screw(s). As the molten materials move forward, the extruder
increases the pressure and temperature which reach a maximum at the mixing zone(s) due to the
intense shearing force in this section (9). The higher temperature and pressure the molten materials
experience as they are transported through the barrel increase the volatility of the moisture content
and permit water and/or other volatile materials to be released. For this reason, locating the vent
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port after the last mixing zone (as for Formulation A3 and D3) will increase the efficiency of
degassing more than if it was located at zone four or zone six (Figure 4-1a).
In this study, the vent port was inserted after the mixing zones where conveying elements
begin. Conveying elements have a larger pitch than other elements, which determine the contact
and surface area of the molten materials. Maximizing the surface area exposed to atmospheric
pressure, and minimizing the internal volume, which kinetically entraps adsorbed moisture,
promotes the release of more vapor from the molten materials. Moreover, the higher pitch of the
conveying elements translates into a higher free screw volume, which provides a greater
opportunity for volatile materials to escape (13). For this reason, the conveying section after the
mixing zone is the preferred location for insertion of the vent port. Furthermore, the pressure
difference between mixing and conveying zones will facilitate the removal of any moisture or
volatile substances, which can be easily evacuated through the vent port.
Drug Content
The uniformity of drug content was measured pre and post-extrusion to ensure uniformity
of mixing, and to assess the chemical stability of carbamazepine. Each formulation was analyzed
by HPLC for drug content. The average drug content ranged from 91.41 to 102.72 % (Table 4-1).
This indicates that carbamazepine was chemically stable with no trace of degradation or weight
loss after extrusion in any of the tested formulations, and further confirms the TGA results.
However, inclusion of a vent port did affect the uniformity of the drug content within each
formulation. carbamazepine distribution was quantified between samples of each formulation
using percent relative standard deviation (%RSD). A higher %RSD indicates a lower uniformity
of drug content between the samples of the same formulation. From an analysis of the HPLC data,
adding a vent port decreased the %RSD values for carbamazepine with Kollidon® 17 PF from 6.84
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to 2.47. This difference indicates that the homogeneity of mixing inside the barrel was enhanced
by the addition of the vent port. This improvement is due to a decrease in the moisture, or any
other volatile substances, that may otherwise interfere with efficient mixing.
Chemical imaging
Only the KlucelTM ELF formulations were examined by chemical imaging since the
Kollidon® 17 PF formulations were extremely brittle, which prevented the application of sufficient
pressure for analysis. Figure 4-4 represents an infrared image of the carbonyl group present in the
amorphous carbamazepine within the extrudates at wavenumber 1671. The pictures were taken at
5.5: µm spatial resolution in transmission mode with a total field of view (FOV) of 300 × 300: µm.
The false color images visually illustrate the location of carbamazepine within the extrudates as
the color intensities are a function of the presence of a spectral band unique to carbamazepine in
these formulations. The blue area indicates an absence of carbamazepine in that region, while red
indicates relatively high carbamazepine concentrations. In Figure 4-4a, a large blue area indicates
a lack of carbamazepine in that region, which translates to inhomogeneity. The images illustrate
that adding a vent port resulted in an improvement in homogeneity, which was optimized by
inserting the vent port at zone nine. Figures 4-4b, c, and d, illustrate differences in the distribution
of carbamazepine as a function of the vent port location. During passage through the extruder, the
temperature and pressure increase and the energy being transferred into the process materials also
increases. As mentioned in section 2.3 regarding the moisture content, inserting the vent port at
zone 9 exhibited a lower moisture content. Thus, by reducing the moisture content (5-6 %) we can
expect this would impact on the distribution of the CBZ within the molten polymer. Even thought
that there was not any mixing zone after zone 9 the conveying element will still impart a moderate
mixing. Thus, the efficacy of degassing is related to the location of the vent port. The results of
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the imaging were in agreement with the HPLC data, both of which confirm an improvement of
mixing after adding the vent port.

a

b

c

d

Figure 4-4. a) Chemical image highlighting the intensity of the carbonyl present in
amorphous carbamazepine a) non-degassed formulation (extrudates A0). b) Chemical
image of formulation degassed at zone four (extrudate A1). c) Chemical image of
formulation degassed at zone six (extrudate A2). d) Chemical image of formulation
degassed at zone nine (extrudate A3).
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Fourier transform infrared spectroscopy (FTIR)
FTIR spectra (Figure 4-5) for pure carbamazepine demonstrated the characteristic peaks of
crystalline carbamazepine form III at 3461 and 3154 cm-1 (19). These peaks were also present,
unchanged, in the physical mixtures of the formulations, which indicates that physical mixing did
not result in inter-molecular interaction between carbamazepine and the polymers. However, these
peaks disappeared in the FTIR spectra of the extruded formulations (Figure 4-5). This confirms
that carbamazepine forms amorphous solid dispersions in the polymeric carrier. Degassing,
however, did not affect the FTIR spectra further, indicating that degassing did not alter the
chemical or physical state of the API.

Figure 4-5. FTIR spectra a) pure CBZ, b: physical mixture of CBZ:Kollidon® 17 PF
(25:75), c) physical mixture of CBZ:KlucelTM ELF (25:75), d) extrudates of CBZ:Kollidon®
17 PF (25:75), e extrudates of CBZ:KlucelTM ELF (25:75).

In-vitro release studies
The results of the dissolution profiling varied among the tested formulations. Figure 4-6
shows that after degassing, the extruded formulations (A3 and D3) demonstrated faster drug
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release than the corresponding formulations (A0 and D0) without degassing. Drug release from
the extruded matrices was found to vary substantially with the percentage of moisture as well as
with the location of the vent port. However, the difference between the drug release profiles of the
degassed and non-degassed formulations was significant for only the first 30 min of the study after
which time they converged. For example, after 10 min, the percentage of drug release from
formulations A0 (non-degassed) and A3 (degassed) were 8.48% and 54.1% respectively; however,
after 90 min the values increased to 91.82% and 92.16% respectively. This may result from further
mixing of the melt, which increases the dispersibility of carbamazepine in the polymeric carrier.
As demonstrated above, degassing during processing enhanced the homogeneity of mixing and the
resulting increased molecular dispersion will increase the wettability and solubilizing effect of the
carrier. In the first few minutes of the test, the drug release is limited by the shell of the capsules,
which then disintegrates so that the drug release becomes dependent on diffusion of carbamazepine
from the surface of the capsule contents. The disintegration rate of the shell is common to all the
formulations, but since degassing affects the distribution of carbamazepine, this could be expected
to be reflected in variability of drug release. The standard deviation during the first 30 min was
high for formulations A0 and D0, and reduced for A3 and D3. After this time, however, most of
the contents of the capsule will be dispersed and all formulations would be predicted to exhibit
similar dissolution rates.
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Figure 4-6. a) In vitro release profiles of pure carbamazepine, degased and non-degassed
Kollidon® 17 PF formulation extrudates. b) In vitro release profiles of pure
carbamazepine, degassed and non-degassed Klucel™ ELF formulation extrudates.
Another factor to consider is energy consumption that is energy applied in the form of temperature
and shearing stress that can convert the crystalline form of carbamazepine into the amorphous
form. This energy can also serve to mix and disperse the carbamazepine within the molten
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polymer. Molten materials with different levels of moisture content have different rheology and
viscosity properties (20). In addition, the presence of moisture or other volatile substances such as
monomers can interrupt the energy distribution and affect the mechanical properties of the product.
Each material has its own heat capacity, which affects the heat distribution within the melt,
including any adherent moisture and other volatile substances, which can partially absorb the
energy and reduce the efficiency of solid dispersion. Differences in composition can therefore have
an effect on the distribution of shear energy and mix intensity. In this study, the morphological
changes that were detected by DSC confirmed that carbamazepine was in the amorphous form in
all the formulations. However, solid dispersions produced by HME can result in a variety of
different forms including solid solutions, glass solutions or suspensions, and simple eutectic
mixtures, as well as the amorphous form in a polymeric carrier. Most often, the resulting solid
dispersion is a combination of a number of types (21). Two different types of mixing can be applied
using the mixing screw elements, distributive mixing and dispersive mixing. Distributive mixing
aims mainly to distribute the carbamazepine throughout the molten polymer matrix while
dispersive mixing results from the application of shear stresses on the extruded materials, which
are sufficient to break any agglomerates down to a smaller particle (22, 23). Thus, degassing may
enhance mixing which will affect the quality of solid dispersion and the subsequent homogeneity
of processed materials.
Processing observations
In this study, the extrusion parameters were held constant for all formulations. Under
constant parameters (feeding rate, temperature, screw speed) the main factor affecting the torque
and the die pressure will be the movement of the materials (24). The software suite of the extruder
recorded the changes in torque and die pressure, every five seconds. Screw torque can monitor by
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electric sensors on the motor and a pressure probe sensor was connected to the die to follow these
during processing. The torque was recorded as a percentage (100% equals 24 Nm), and pressure
was measured in bar (25). It was reported that pressure and torque fluctuations change extrusion
processing behavior (26). In this study, different trends in torque and die pressure were observed.
Monitoring the screw torque and extruder pressure demonstrated a correlation with the conveying,
mixing, and melting of the extrudate. Understanding and adjusting the parameters involved in the
process are necessary to improve the extrusion efficacy and achieve the desired quality in the
product.
Torque
Torque is the amount of motor force required to move the material through an extruder
(27). For most extruders, the torque applied is monitored during the process, and different
parameter adjustments are applied based on this measurement. Unlike other industries, where a
high torque is required to process hard materials such as ceramic powders, for pharmaceutical
HME applications, a low torque is preferable to increase the free volume resulting in higher
throughput and providing more intense mixing at lower extrusion temperatures (13). Analysis of
the torque data showed that the average motor torque percentage changed as the location of the
vent port moved. The torque averages for carbamazepine with Kollidon® 17 PF were 19.9, 25.5,
23.9 and 20.4% for A0, A1, A2, and A3 respectively. Location of the vent port at zone four
(formulation A1) initially increased the torque which gradually decreased as the vent port was
moved toward the die (Table 4-1). This phenomenon is due to a combination of dilution and the
plasticizing effect of adsorbed moisture, which has been reported to be associated with mechanical
behavior changes that may affect the torque (28). Moisture may act as a diluent and decrease the
total viscosity of the material inside the barrel resulting in an increase in the flow rate of molten
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materials without increasing the torque (29). This explains the decrease in torque when the vent
location was changed from zone four to zone six. Formulation A1 showed a relatively higher
torque than that shown by formulations A2 or A3, since the moisture was removed earlier during
the process. Formulation A3 has the lowest torque value as the moisture was utilized as a
plasticizer for a longer period than that during the processing of formulations A1 or A2. However,
similar torque values were obtained, albeit with different standard deviations when comparing
equivalent formulations without degassing (A0) and with degassing (A3). Degassing was able to
reduce the fluctuations in the torque measurement even if the average values of A0 and A3 were
very similar. Reducing the torque fluctuations will impact the die pressure and, consequently, the
physicochemical properties of the final product (30).
Furthermore, the torque will affect the specific mechanical energy (SME) consumption, which is
an important factor to consider for scaling up the process (23).

SME =

Consumed motor power
τ. N
=
Q
τmax . Nmax

Where τ is torque (%), Q is the feeding rate in kg/h, and N is the screw speed (rpm).
Over the last ten years, HME has demonstrated relatively simple scalability, which is a
considerable advantage with respect to the potential of the technology in pharmaceutical
production. Process parameters play a significant role during scale up procedures and one of the
most critical issues during the scale up process is torque limitation. For large scale production, the
torque will affect several aspects including energy consumption, product quality, consistent flow,
and maximum feeding rate (8) and it is therefore critical to optimize this parameter. As already
described, degassing represents an apparent advantage in terms of minimizing the variations in
torque values as well as an overall control of torque during processing. The scale up of melt
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extrusion processes, however, is still challenging due to a limited insight into the process (31). A
recent survey of the literature revealed that no significant progress has yet been reported regarding
the implications of degassing on pharmaceutical processing operations. A deeper understanding of
the parameters affecting the process may be utilized to develop monitoring tools for quality
management systems and, as such, can assist in the application of quality by design (QbD)
principles.
Pressure
The second parameter analyzed in this study was die pressure which is the force exerted
on the materials within the die, responsible for compression/densification as the molten material
is forced through (13). Die pressure is dependent on the extruder temperature, screw speed,
material properties, and feeding rate (20). In this study, the addition of the vent port had no
significant effect on the absolute value of die pressure. However, pressure fluctuations
dramatically decreased and a relatively constant value for die pressure was maintained after adding
the vent port (Table 4-1), which is indicative of process stability and a steady state. The die plays
an essential role in forming and shaping the extrudate, as well as in determining the physical
appearance of the final product (32). The last zone of the extruder (just prior to the die) is
responsible for moving the materials to the die and is the site of maximum backpressure. If the
pressure is constant, the movement of the in-process materials will be more uniform, which will
be reflected in the shape of the product and an overall uniformity in physical appearance.
A constant pressure and torque are also necessary for effective and homogeneous mixing. Also,
Minimizing fluctuations in pressure is beneficial for in-line quality prediction tools as shown in a
recent study, where the researchers used NMR as a prediction tool, following the influence of die
pressure on in-line Raman spectroscopy monitoring of the solid state of the final product (33).
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Different die pressures affected the quality of the NMR results with lower variations in die pressure
associated

with

improved

output,

which

will

facilitate

QbD

studies.

Larger extruders have larger screw diameters and, thus, an increased volume inside the barrel. As
a result, it is expected that with larger extruders (relative to the 16 mm used in this study) the
effects of degassing will be more pronounced as there is more moisture retaining material in
process per unit time and proportionally more internal volume within the polymer melt to trap any
volatile materials. After degassing, more of the total energy applied to the system, including barrel
temperature, will be imparted to the constituents of interest, namely the API and carrier. Thus,
degassing should effectively enhance the output while potentially decreasing the cost of production
through enhanced energy utilization.
Shape
Figure 4-7 illustrates the difference in appearance between extrudates formed with or
without degassing. The decrease in moisture content was associated with an improved physical
appearance of the extrudates. Extrudates that were produced without a vent port appeared visually
obstructed with irregularities on both the surface and the interior. In contrast, the degassed
extrudates appeared clear and consistent with few abnormalities; however, it should be noted that
this was partially because of the location of the vent port. The physical appearance and hardness
were altered by the addition of the vent port. Formulation A0 could be described as brittle and
irregular, while formulation A3 was hard, clear and consistent, bearing no trace of entrapped gas
pockets. The appearance of gas pockets within an extruded material is due to the moisture flashoff, which occurs after the material leaves the pressurized die and is exposed to a sudden decrease
in pressure (20). This flash-off occurs very rapidly, and can be detrimental to the shape of the final
product. In the last zone of the extruder, there are discharging elements with single flight geometry,
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designed to push the material into the die, ensure a uniform delivery rate through the die cavity,
and to generate the required extrusion pressure. It is important that the extruder screw at this zone
should be filled with molten materials to maintain a constant shape and uniform product
production, and to prevent foaming of the extrudates or inclusion of air bubbles which are primarily
the result of moisture and/or air entrapment in the feeder zone (32). The presence of any volatile
materials can alter the pressure and the free volume at the discharging zone, which may
subsequently affect the uniformity and the shape of the product. Constant pressure, resulting from
the absence of entrapped gasses, should facilitate the extrusion of a product with uniform
appearance from the discharging elements. After degassing, the extrudates became uniform and
consistent in shape than the extrudates without degassing (Figure 4-7). Additionally, the
appearance of gas bubbles in the extrudates decreased in the formulation A3, with a corresponding
reduction in the moisture content.
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Figure 4-7. Optical microscope photographs of fresh extrudates of Kollidon® 17 PF with
carbamazepine.
Stability Study
After three months of storage at 40°C and 75% RH, the in vitro release was compared to
freshly produced extrudates. The release profiles of carbamazepine varied between the
formulations, with a general trend to a decrease in the release over time. This was particularly
noticeable in the formulations processed without degassing, and with a dependency on the location
of the vent port at the time of processing. The similarity factor for each formulation increased as
the vent port moved moved from zone 4 to zone 9, with the opposite true for the dissimilarity
factor (Table 4-2). These differences are attributed to the percentage of moisture content in each
formulation, which as discussed previously, is dependent on the location of the vent port. Moisture
is a prime enabler of re-crystallization processes for most thermodynamically unstable solid
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dispersion systems although intense mixing could help retard any nucleation and crystal growth of
carbamazepine polymorphs from the amorphous phase. Moreover, as previously indicated,
degassing improved the uniformity of mixing which was also enhanced by removing air, moisture
and other volatile substances. Inserting the vent port at zone nine permits the utilization of
entrapped moisture as a plasticizer but then facilitates its removal just prior to the material exiting
the die, thereby effectively utilizing the advantages of entrapped moisture and then subsequent
purging the system of entrapped gas before deleterious effects can be imparted to the extruded
material.

Table 4-2. Stability study data for all the formulations after three months.
Formulation

Similarity factor f2

Dissimilarity factor f1

A0-3M
A1-3M
A2-3M
A3-3M
D0-3M
D1-3M
D2-3M
D3-3M

36.50
45.95
71.67
68.24
50.36
53.64
66.82
66.47

22.90
13.62
3.93
4.17
16.03
12.80
5.97
6.38
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CONCLUSION
The novel findings of this study lead to the recommendation that proper degassing, placing
at least one vent port after the last mixing zone (wherever applicable) should be a part of any hot
extrusion processes. Degassing can enhance the properties of the final product by removing
residual moisture, volatile substances and subsequent air bubbles, thereby facilitating the
production of consistent, smooth uniform extrudates. Additionally, venting of entrapped gasses
will reduce the torque and pressure variations, and have a positive impact on the homogeneity and
efficiency of the process. The consideration of the devolatilization process and its influence is of
particular significance during scaling up of the process. The degassing process should be evaluated
on a case by case basis, dependent primarily on the nature of the properties (i.e. low molecular
weight polymers, solvent usage, volatile materials, hygroscopic materials, etc.) of the materials
(API, stabilizers, antioxidant, plasticizers, pigments and other additive) being utilized.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
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5.1 Optimizing the Hot Melt Extrusion Processing Parameters
 Soluplus® was able to produce a solid dispersion system with a high melting point API
(CBZ).
 All of the extruded formulations have demonstrated a higher dissolution rate compared to
the pure drug.
 Processing parameters showed significant effects on the properties of hot-melt extrudates.
 Design of experiment was successfully indicate the most significant factor with minimum
numbers of experiment runs.
 A full two level factorial design was able to suggest optimize processing parameters with
a low error percentage.
 Screw configuration was shown a significant influence on the properties of the solid
dispersion.
 Temperature and screw design had significant effect on dissolution rate of CBZ
compared to screw speed as the processing parameters.
5.2 Stability-enhanced Hot-melt Extruded Amorphous Solid Dispersions via Combinations
of Soluplus® and HPMCASHF:
 A novel combination of Soluplus® and HPMCAS-HF polymers were evaluated for
solubility enhancement of a low water soluble API.
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 CBZ was completely miscible in the polymer blends of Soluplus® and HPMCAS-HF up
to 40% drug loading.
 Drug loading, and polymers ratio showed a significant effect on the dissolution rate of
CBZ.
 DSC and XRD data confirmed the formation of amorphous solid dispersions of CBZ in
the polymer blends of Soluplus® and HPMCAS-HF.
 All of the extruded formulations have demonstrated a higher dissolution rate than the
pure drug.
 The dissolution rate of the CBZ was increased with increasing concentration of Soluplus®
in all tested formulations indicating that the Soluplus® is playing a key role in the
dissolution rate enhancement of the drug.
 HPMCAS-HF was able to stabilize the solid dispersion by increasing the glass transition
temperature and hydrogen bond formation.
 All of the extruded formulations were found to be physically and chemically stable at
40°C, 75% RH for a period of 12 months.
5.3 Influence of Degassing on Hot-Melt Extrusion Process
 Degassing during the process was enhancing the homogeneity of mixing by removing air,
moisture and other volatile substance.
 This molecular dispersion enhancement will increase the wettability and the solubility
effect of the carrier.
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 Effective degassing was revealed different impact such as increase free volume, reduce
residual moisture, visual appearance, mechanical properties, and prevent bubbling or
foaming.
 All of the degased extrudates exhibited faster release rates as compared to non degased
extrudates.
 Degassing had a significant impact on the dissolution rate, cross-section uniformity and
extrudates stability, particularly with hygroscopic materials (such as Kollidon 17 PF).
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